Soumya Chakravarty, MD, PhD, FACP, FACR, senior director, strategic lead rheumatology therapeutic area, Johnson & Johnson Innovative Medicine, highlights the APEX study’s findings that Tremfya (guselkumab) is the first IL-23 inhibitor to significantly inhibit structural damage progression in biologic-naïve psoriatic arthritis patients, offering a multi-domain, early treatment option with a consistent safety profile to help preserve long-term function and quality of life.
The post Shaping First-Line Therapy Decisions in PsA first appeared on Physician’s Weekly.
